期刊文献+

紫杉醇对子宫内膜癌细胞CYP1B1基因表达的影响 被引量:3

下载PDF
导出
摘要 目的:探讨子宫内膜癌细胞CYP1B1基因表达对紫杉醇化疗耐药性的相关性。方法:以Ishikawa细胞经过细胞培养诱导其表达,在不同时间、不同浓度的给予紫杉醇,采用MTT法测定细胞生长,通过PCR技术检测CYP1B1 mRNA表达检测、Western blot检测蛋白表达,观察CYP1B1基因表达情况。结果:子宫内膜癌Ishikawa细胞可以诱导CYP1B1基因表达。紫杉醇了明显抑制子宫内膜癌细胞,不同浓度抑制率不同。在0、0.1、1.0、5.0、10.0、30.0μg/m L抑制率分别为1.38%、25.41%、40.37%、59.78%、73.67%、89.34%。随着药物浓度和时间的增加,细胞存活呈负相关(P<0.05)。结论:CYP1B1基因在子宫内膜癌细胞中呈高表达,在子宫内膜癌Ishikawa细胞体外化疗中起抑制作用。
出处 《黑龙江医药科学》 2015年第3期84-85,共2页 Heilongjiang Medicine and Pharmacy
基金 黑龙江省卫生计生委科研课题 编号:2014-221
  • 相关文献

参考文献6

  • 1朱壮彦,糜若然.卵巢癌细胞系A2780紫杉醇体外化疗后CYP1B1基因表达差异研究[J].中国实用妇科与产科杂志,2008,24(2):143-145. 被引量:6
  • 2孙婷婷,刘丽娜,周友珍.线粒体DNA突变与子宫内膜癌紫杉醇耐药相关性研究[J].中国妇产科临床杂志,2013,14(4):335-339. 被引量:1
  • 3De Graan AJ, Elens L, Staid M, et 8.1. A pharmacogenetie predic- tive model for paclitaxel clearance based on the DMET plafform[ J]. Clin Cancer Res, 2013,19(18) :5210 -5217.
  • 4Marsh S, Somlo G, Li X, et al. Pharmacogenetic analysis of paclita- xel transport and metabolism genes in breast cancer[ J]. Pharmaeog- enomics J, 2007, 7 (5) :362 - 365.
  • 5Murray GI, Taylor MC, MeFadyen MC, et al. Tumor - specific ex- pression of cytochreme P450 CYP1 B1 [ J]. Cancer Research, 1997, 57(14) : 3026 -3031.
  • 6Li Y1, Tan SQ, Ma QH, et al. CYP1B1 C4326G polymorphism and susceptibility to cervical cancer in Chinese Han women [ J ]. Tumour Biol. 2013. 34(6) :3561 -3567.

二级参考文献12

  • 1Buters J, Leticia QM, Schober W, et al. CYP1B1 determines susceptibility to low doses of 7,12-dimethylbene [ α ] anthraceneindnced ovarian cancers in mice: correlation of CYPI Bl-mediated DNA adduets with carcinogenicity [ J ]. Carcinogenesis, 2003, 24(2) :327-334.
  • 2Fujita K. Cytochrome P450 and anticancer drugs[ J ]. Curr Drug Metab, 2006, 7 ( 1 ) : 23-37.
  • 3Martinez C, Gareia-Martin E, Pizarro RM, et al. Expression of paclitaxel inactivating CYP3A activity in human colorectal cancer: implications for drug therapy, [ J ]. Br J Cancer, 2002. 87 (6) : 681-686.
  • 4Murray GI. The role of eytochrome P450 in tumour development and progression and its potential in therapy [ J]. J Pathol,2000, 192: 419-426.
  • 5McFadyen MCE, Breeman S, Payne S, et al .ical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1 [ J ]. J Histochem Cytochem, 1999,47 : 1457 -1464.
  • 6McFadyen M, Cruickshank 1, McLeod H, et al. Cytochrome P450 over-expression in primary and metastatic ovarian cancer [J]. Br J Cancer,2001,85(2):242-246.
  • 7Rochat B. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism [J ]. Clin Phannacokinet, 2005, 44(4) : 349-366.
  • 8McFadyen M, McLeod H, Melvin WT, et al. Cytoehrome P450 CYP1B1 protein expression : a novel mechanism of anti-caneerdrug resistance [ J ]. Biochem Pharmacol, 2001 , 62 ( 9 ) : 207- 212.
  • 9Sato S, Kigawa J, Kanamori Y, et al. Activity of docctaxel in paelitaxel-resistant ovarian cancer ells [ J ]. Cancer Chemother Phannacol, 2004, 53 ( 3 ) : 247-252.
  • 10McFadycn MCE, Melvin WT, Murry Gl, et al. Cytochrome P450 enzymes: a novel options for cancer therapeutics [ J ]. Mol Cancer Ther,2004, 3:363-371.

共引文献5

同被引文献10

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部